Northwestern Medicine investigators have discovered that specialized immune cells within the glioblastoma tumor microenvironment use a unique “feeding” mechanism that promotes tumor growth and treatment resistance, according to findings published in the journal Cell Metabolism.

Vagal nerve stimulation (VNS) is a well-tolerated procedure for patients with medication-resistant and non-focal epilepsy. It does, however, have potential complications (e.g., hoarseness and cough) thought to be from vagus nerve irritation. These arise postoperatively and generally improve without intervention. If these symptoms present later or do not improve, it suggests a more insidious etiology. Herein we report the case of a patient in their 50s with medication-resistant epilepsy, who subsequently underwent VNS electrode array and pulse generator implantation to aid seizure management. Three years after the initial implantation, the patient experienced vocal cord paralysis and neck pain following a syncopal fall. The pain radiated to their jaw and chest and was eliminated when their VNS was turned off. The patient was taken to the OR for removal and replacement of their entire VNS system. Their original electrodes were unable to be removed secondary to being scarred in place. The patient’s preoperative pain symptoms completely resolved after the removal of their old VNS and implantable pulse generator (IPG) and replacement with a new system 14 days postoperatively. While short-term postoperative sequelae and lead fractures/displacements have been reported in the literature, this is the first case to our knowledge of a patient experiencing a likely symptomatic traction injury without displacement of the VNS coils or obvious vagus nerve injury. Furthermore, the removal and replacement of the entire VNS system led to complete relief of their presenting symptoms.

Northwestern Medicine scientists have identified how one gene connects glioblastoma stem cell self-renewal to microglia immunosuppression in glioblastoma, according to a new study published in Nature Immunology.

Northwestern Medicine identified a novel therapeutic agent that is effective in treating metastatic breast cancer and brain metastases with minimal side effects.

Chicago's Very Own source for breaking news, weather, sports and entertainment.

The US Food and Drug Administration (FDA) mandated folic acid fortification of all enriched cereal grains in 1996, and this regulation resulted in a reduction of neural tube defect (NTD)–affected pregnancies ...

Northwestern Medicine investigators led by Amy Heimberger, MD, PhD, have discovered a new mechanism in which cancer-associated fibroblasts are associated with tumor grade and mediate immune suppression in glioma tumors.

Scientists have recently found a highly accurate way to predict the best treatment for patients with meningioma based on patterns of gene expression in their tumors. In this Better Edge podcast episode, Stephen T. Magill, MD, PhD, of Northwestern Medicine Neurological Surgery, discusses an innovativ

MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas. Accurate results depend on sufficient tumor cellularity, but histologic estimates of cellularity are subjective. We sought to determine whether driver mutation variant allelic frequency (VAF) could serve as a more objective metric for cellularity and identify possible false-negative MGMT samples. Among 691 adult-type diffuse gliomas, MGMT promoter methylation was assessed by pyrosequencing (N = 445) or DNA methylation array (N = 246); VAFs of TERT and IDH driver mutations were assessed by next generation sequencing. MGMT results were analyzed in relation to VAF. By pyrosequencing, 56% of all gliomas with driver mutation VAF ≥ 0.325 had MGMT promoter methylation, versus only 37% with VAF < 0.325 (p < 0.0001). The mean MGMT promoter pyrosequencing score was 19.3% for samples with VAF VAF ≥ 0.325, versus 12.7% for samples with VAF < 0.325 (p < 0.0001). Optimal VAF cutoffs differed among glioma subtypes (IDH wildtype glioblastoma: 0.12–0.18, IDH mutant astrocytoma: ~0.33, IDH mutant and 1p/19q co-deleted oligodendroglioma: 0.3–0.4). Methylation array was more sensitive for MGMT promoter methylation at lower VAFs than pyrosequencing. Microscopic examination tended to overestimate tumor cellularity when VAF was low. Re-testing low-VAF cases with methylation array and droplet digital PCR (ddPCR) confirmed that a subset of them had originally been false-negative. We conclude that driver mutation VAF is a useful quality assurance metric when evaluating MGMT promoter methylation tests, as it can help identify possible false-negative cases.

Chicago's Very Own source for breaking news, weather, sports and entertainment.

Northwestern Medicine McHenry Hospital now offers pituitary tumor resection surgery - going through the nose and nasal cavity to remove pituitary tumors.

Scientists have uncovered a genetic explanation for a subset of common brain tumors, according to a study published in Nature Communications.

Northwestern Medicine identified a novel therapeutic agent that is effective in treating metastatic breast cancer and brain metastases with minimal side effects.